Sirnaomics, Inc., a biopharmaceutical company engaged in the discovery and development of RNAi therapeutics against cancer and fibrotic diseases, today announced the results showing STP705 inhibits the growth of HuCCt-1 (a human cholangiocarcinoma cell line) as a xenograft tumor in nude mice. The work is published as an online abstract at the 2019 American Society of Clinical Oncology Annual Meeting.
Cholangiocarcinoma (CCA) is the second most common form of incurable hepatobiliary cancer and represents a massive health care burden worldwide with no effective treatment. Over expression of the genes for TGF-β1 and COX-2 have been well-characterized as playing key roles in tumorigenesis of CCA. STP705 consists of a combination of 2 siRNAs silencing the TGF-β1 and COX-2 genes delivered using a polypeptide nanoparticle delivery system based on Histidine-Lysine co-Polymer (HKP). We have demonstrated that STP705 inhibits the growth of HuCCt-1 xenograft tumors in nude mice (a human cholangiocarcinoma model) and the data is presented in the abstract.
Sirnaomics, Inc., a leading privately held biopharmaceutical company for discovery and development of RNAi therapeutics, is a Delaware corporation headquartered in Gaithersburg, Maryland, USA, with subsidiaries in Suzhou and Guangzhou, China. The Company’s mission is to develop novel therapeutics to alleviate human suffering and advance patient care in areas of high unmet medical need. The guiding principles of the company are: Innovation, Global Vision with a Patient Centered focus. Members of the senior management team have a great deal of combined experience in the biopharmaceutical industry, financial, clinical and business management in both the USA and China. The company is supported by funding from institutional investors and corporate partnerships. Sirnaomics has developed a strong portfolio of intellectual property with an enriched product pipeline. The therapeutic areas of focus include oncology and anti-fibrotic therapeutics. Learn more at www.sirnaomics.com.